Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28

Mythily Srinivasan, Ingrid E. Gienapp, Scott S. Stuckman, Connie J. Rogers, Scott D. Jewell, Pravin T.P. Kaumaya, Caroline C. Whitacre

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


The B7:CD28/CTLA-4 costimulatory pathway plays a critical role in regulating the immune response and thus provides an ideal target for therapeutic manipulation of autoimmune disease. Previous studies have shown that blockade of CD28 signaling by mAbs can both prevent and exacerbate experimental autoimmune encephalomyelitis (EAE). In this study, we have designed two CD28 peptide mimics that selectively block B7:CD28 interactions. By surface plasmon resonance, both the end group-blocked CD28 peptide (EL-CD28) and its retro-inverso isomer (RI-CD28) compete effectively with the extracellular domain of CD28 for binding to B7-1. Both the CD28 peptide mimics inhibited expansion of encephalitogenic T cells in vitro. A single administration of EL-CD28 or RI-CD28 peptide significantly reduced disease severity in EAE. Importantly, we show that either CD28 peptide mimic administered during acute disease dramatically improved clinical signs of EAE, suppressing ongoing disease. The ratio of CD80: CD86 expression was significantly lower on CD4+ and F4/80+ spleen cells in CD28 peptide-treated mice. Peripheral deletion of Ag-specific CD4+ T cells occurs following in vivo blockade of CD28 with synthetic CD28 peptides.

Original languageEnglish (US)
Pages (from-to)2180-2188
Number of pages9
JournalJournal of Immunology
Issue number4
StatePublished - Aug 15 2002

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28'. Together they form a unique fingerprint.

Cite this